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Abstract
Appropriate antibiotic therapy in patients with severe sepsis and
septic shock should mean prompt achievement and maintenance
of optimal exposure at the infection site with broad-spectrum anti-
microbial agents administered in a timely manner. Once the
causative pathogens have been identified and tested for in vitro
susceptibility, subsequent de-escalation of antimicrobial therapy
should be applied whenever feasible. The goal of appropriate
antibiotic therapy must be pursued resolutely and with continuity, in
view of the ongoing explosion of antibiotic-resistant infections that
plague the intensive care unit setting and of the continued
decrease in new antibiotics emerging. This article provides some
principles for the correct handling of antimicrobial dosing regimens
in patients with severe sepsis and septic shock, in whom various
pathophysiological conditions may significantly alter the pharmaco-
kinetic behaviour of drugs.
Introduction
During the last half decade of the 20th century, several major
studies conducted in critically ill patients in both Europe and
the USA demonstrated unequivocally that initial inappropriate
antimicrobial treatment for pneumonia was associated with
increased mortality [1]. It is of note that both in these earlier
studies and in subsequent confirmatory ones [2,3], the
appropriateness of treatment was typically assessed in terms
of antimicrobial coverage, defined as the use of an agent to
which a pathogen is susceptible [4]. In contrast, less atten-
tion - if any - was given to the fact that failures of anti-infective
therapy in the intensive care unit (ICU) setting might occur
not only as a consequence of inappropriate choice but also
with inappropriate dosing, potentially leading to suboptimal
exposure to the broad-spectrum antimicrobial agent at the
infection site, even if it is administered in a timely manner [5].
The issue of dosing is of particular relevance in patients with
severe sepsis or septic shock, in whom various pathophysio-
logical conditions may significantly alter the pharmacokinetic
behaviour of drugs [6]. Importantly, pharmacokinetic studies
to define drug dosages for regulatory purposes are usually
carried out in healthy volunteers, who by definition are not
patients. Consequently, it is not surprising that dosing
regimens of several antimicrobials are expected to be
significantly different in ICU patients from those suggested
for clinically stable patients.
The concept of the antimicrobial therapy
puzzle
A recent study assessed the outcomes of bacteraemia due to
Pseudomonas aeruginosa according to antimicrobial choice
and to piperacillin-tazobactam susceptibility in two parallel
retrospective cohorts [7]. It offers an opportunity to raise
some interesting observations on this topic. The first cohort
included 34 patients with bacteraemia due to P. aeruginosa
with borderline susceptibility to piperacillin-tazobactam (mini-
mum inhibitory concentrations [MICs] of 32 or 64 mg/l). In
this cohort the 30-day mortality rate was significantly higher
among those patients empirically treated with this antibiotic
(n = 7) than in those treated with other effective anti-
pseudomonal antimicrobials (n = 27; 85.7% versus 22.2%,
P = 0.004). Conversely, in the second cohort, which included
49 patients with bacteraemia due to bacterial isolates that
were more susceptible to piperacillin-tazobactam (MICs
≤16 mg/l), the mortality rate was not statistically different
between piperacillin-tazobactam and control groups (30.0%
versus 20.5%, P = 0.673).
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Although this study poses an interesting question about the
necessity of reducing the microbiological breakpoints for
piperacillin-tazobactam, several aspects deserve some
consideration [7]. First, details of drug dosages were not
provided. There is evidence that standard dosages of pipera-
cillin (4 g given over 30 minutes every 6 hours), by ensuring
very low trough plasma levels, may not be sufficient in ICU
patients with enhanced renal function [8], and this suggests
that drug dosage may be a major issue in this setting.
Second, clinical outcome was not related to the immuno-
logical status of the patients. In this regard, the efficacies of
two different administration schedules of ceftazidime were
compared in an interesting experimental animal model of
pneumonia due to Klebsiella pneumoniae [9]. In immuno-
competent animals the dose needed to ensure that 50% of
the rats survived was similar for both continuous infusion and
intermittent infusion every 6 hours (0.36 versus 0.35 mg/kg).
In contrast, in immunocompromised animals the 50% protec-
tive dose was 15-fold lower when using continuous infusion,
even if higher doses for both administration schedules were
needed (1.52 mg/kg versus 24.37 mg/kg). This study supports
the general contentions that the immunological status of the
patient may be relevant to infection response and that
continuous infusion may be especially helpful for improving the
efficacy of β-lactams in immunocompromised patients [10].
Finally, in that study [7] it was clearly stated that no patient
received the drug by prolonged or continuous infusion.
However, in vivo experiments have shown that bacterial killing
with penicillins is slow and may become maximal when the
time for which the antibiotic concentration exceeds the MIC
of the infecting pathogen (t>MIC) is equal to 50% to 60% of
the dosing interval [11]. Of note, a recent Monte Carlo
simulation study assessed the theoretical cumulative fractions
of response with the standard 16/2 g daily dosage of
piperacillin/tazobactam for the treatment of P. aeruginosa
infections (with a target t>MIC of 50%), according to differ-
ent administration schedules [12]. The percentage of
response was increased by about 10% when simulating
3-hour prolonged infusion or continuous infusion in com-
parison with 30-minute intermittent infusion (around 90%
versus 80%). This suggests that, under the same daily dose,
extended infusion or continuous infusion - by ensuring more
sustained trough levels - may be worthwhile in terms of in-
creasing the clinical efficacy of time-dependent antimicrobials.
From these considerations, it becomes evident that in order
to optimize antibiotic therapy in critically ill patients it is not
sufficient to make the correct choice on the basis of the anti-
biogram. It is also mandatory to consider timely administration
of the right dose at the right schedule, according to the
pathophysiological and immunological status of the patient.
Otherwise stated, the benefit of administering the correct
antibiotic choice in terms of spectrum of activity can be
nullified by delayed treatment or insufficient dosing, and this
is to be avoided. Indeed, it should not be overlooked that
assessment of the in vitro bacterial susceptibility is but one of
the pieces needed to solve correctly the ‘antimicrobial
therapy puzzle’ (Figure 1) [5]. Particular attention should also
be given to the infection site. Drug penetration into infected
tissues may be affected by the peculiar pharmacokinetic
properties of antimicrobials (Figure 2). Given that similar
antibiotics may have very different diffusion profiles, know-
ledge of antibiotic concentration at the site of infection is of
paramount importance in terms of optimizing antimicrobial
therapy in patients with severe sepsis. As a general rule,
hydrophilic antimicrobials, as opposed to lipophilic ones, may
diffuse only slowly and partially in deep-seated infection sites.
Overall, this appears to support the view that dosages higher
than needed for the treatment of bacteraemia and/or
improved administration schedules are needed to treat deep-
seated infections (such as pneumonia and intra-abdominal
infections), with hydrophilic antimicrobials to ensure optimal
pharmacodynamic exposure at the infection site [5,13,14].
Moreover, it should be borne in mind that drugs with excellent
in vitro activity against multiresistant pathogens may be
inactivated at the infection site, as in the case of daptomycin,
which is not applicable to lung infections because of its
inactivation by pulmonary surfactant [15]. Finally, drug
concentrations at sites of infection may be affected also by
the pathophysiological setting, which may change
significantly in patients with severe sepsis even during the
brief period of a few hours [5,16].
Figure 1
The antimicrobial therapy puzzle. MIC, minimum inhibitory
concentration. Reproduced with permission from Pea and Viale [5].Specific pathophysiological and
pharmacokinetic/pharmacodynamic
characteristics in critically ill patients with
severe sepsis/septic shock
Recent international guidelines for the management of severe
sepsis and septic shock (Surviving Sepsis Campaign) [16]
included three important recommendations about anti-
microbial therapy: always begin intravenous antibiotics within
the first hour after severe sepsis and septic shock are recog-
nized; use broad-spectrum agents with good penetration into
the presumed site of infection; and reassess the antimicrobial
regimen daily to optimize efficacy, prevent resistance, avoid
toxicity and minimize costs. Adherence to these recommen-
dations requires an awareness that drug pharmacokinetics in
critically ill patients may undergo significant changes because
of the pathophysiology of sepsis [6].
Regarding the optimal dosage to start antimicrobial therapy, it
must be considered that the target plasma concentration (Ct)
that is achieved with the first dose - loading dose (LD) -
depends solely on the volume of distribution (Vd) of the drug
(LD = Ct × Vd). Of note, capillary leakage and fluid resus-
citation [17], by expanding the extracellular fluid contents,
may enlarge the Vd of antimicrobials in patients with severe
sepsis and septic shock, such that Ct may be decreased
when using the standard LD [6].
As a general rule, this ‘dilution effect’, the so-called ‘third
spacing’ phenomenon, is much more relevant in hydrophilic
agents such as β-lactams, aminoglycosides and glycopeptides,
which selectively distribute to the extracellular space (Figure 2).
Joukhadar and coworkers [18] showed that the peak levels and
area under the plasma concentration-time curve (AUC) of
piperacillin after a single standard 4 g intravenous dose were
several fold lower, either in plasma or in the interstitium of soft
tissues, in patients with septic shock than in correctly matched
healthy volunteers. Likewise, the initial peak plasma concen-
trations of gentamycin and tobramycin following a 3 mg/kg LD
in critically ill surgical patients with life-threatening Gram-
negative infections were found to be lower than desired
(<8.3 mg/l) in about half of the patients, and greater LDs - by at
least 20% to 25% - were advocated [19]. Therefore, higher
than standard LDs of β-lactams, aminoglycosides or glyco-
peptides should be administered to ensure optimal exposure at
the infection site whenever treatment is begun in patients with
severe sepsis or septic shock.
Importantly, the need for appropriate loading at the
commencement of therapy is independent of the patient’s
renal function. This means that initial loading is especially
important in order to avoid the risk of underexposure with
renally excreted drugs that have a very long elimination half-
life. For instance, in the absence of loading, several days may
be required to achieve therapeutically effective concentra-
tions of teicoplanin. We conducted a retrospective study in
which therapeutic drug monitoring (TDM) results were
analyzed in critically ill patients over a 7-year period in our
hospital [20]. We observed that within the first 4 days of
therapy, appropriate LDs of teicoplanin (400 mg every
12 hours at least three times) were administered to only one-
third of patients (78 out of 202). Interestingly, the percentage
of patients receiving appropriate loading was inversely
correlated with their degree of renal function, decreasing from
60.4% in the case of normal renal function to 26.8% and 5.5%,
respectively, in cases of moderately or totally impaired renal
function. The resulting suboptimal concentrations (<10 mg/l),
persisting in most of the patients at day 4 of treatment, could
have negatively affected outcomes with teicoplanin.
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Figure 2
Classification of antimicrobials according to their solubility and pharmacokinetic/pharmacodynamic properties. Reproduced and adapted with
permission from Pea and colleagues [6] and from Pea and Viale [5].Conversely, for lipophilic antibiotics (fluoroquinolones, macro-
lides, tetracyclines, chloramphenicol, rifampicin and oxazo-
lidinones) the ‘dilution effect’ in the extracellular fluids during
severe sepsis may be mitigated by the rapid redistribution of
the drug to the interstitium from the intracellular compartment,
which acts as a reservoir, such that the decrease in Ct after
standard dosages should be less relevant [6]. Interestingly, it
was recently shown that - compared with healthy volunteers -
the severity of sepsis had no substantial effect in terms of
decreasing the peak plasma concentration (Cmax) and AUC of
a lipophilic agent, namely linezolid, after a single 600 mg
standard dose [21]. This was the case both in plasma and in
the interstitium of soft tissues, although a high inter-individual
variability was observed. On this basis, it may be speculated
that, in contrast to observations with hydrophilic anti-
microbials, standard dosages of lipophilic antimicrobials may
frequently ensure adequate loading even in patients with
severe sepsis or septic shock.
Once appropriate initial loading is achieved, it is mandatory to
reassess the antimicrobial regimen daily, because the
pathophysiological changes that may occur, even during a
brief period of a few hours, may significantly affect drug
disposition in the critically ill patients. Of note, timely and
accurate correction of maintenance doses of antimicrobials
that are almost completely excreted by the renal route as
unchanged moiety should be based on daily assessment of
renal function. This is crucial for hydrophilic antimicrobials (β-
lactams, aminoglycosides and glycopeptides) and for
moderately lipophilic antimicrobials (ciprofloxacin and levo-
floxacin). Estimation of creatinine clearance (CLCr) with the
Cockcroft and Gault formula [22] may safely be applied to
assess glomerular filtration rates in recently hospitalized
patients. A recent study confirmed that during the day after
admission CLCr estimates correlated highly with CLCr measured
over 24 hours among 359 ICU patients (r2 = 0.8357) [23].
Conversely, direct measurement of ClCr rather than
estimation should be performed for accurate assessment of
glomerular filtration rate in patients with a lengthy hospital
admission (>1 month). In fact, overestimation of CLCr may be
expected whenever the daily output of creatinine from
muscles is impaired by the degree of muscle loss that may
occur when a patient is bedridden long term [23,24].
It is well known that lower than standard dosages of renally
excreted drugs must be administered in the presence of
impaired renal function (Table 1). Renal failure may be the
consequence of myocardial depression, which can occur as
sepsis progresses and which may lead to decreased organ
perfusion, but it can be also precipitated by nephrotoxic
drugs (vancomycin, aminoglycosides and furosemide) or
iodinated contrast agents. In renal failure, the dosage of toxic
antimicrobials such as aminoglycosides and vancomycin is
usually reduced. However, dosage reduction is less fre-
quently considered for β-lactam antibiotics, even though their
accumulation may result in an often underdiagnosed
neurological toxicity [25-27]. Indeed, drug accumulation
leading to safety issues may also be the consequence of
impaired renal elimination by inhibitors of tubular secretion
(as in the case of probenecid with β-lactams) and/or of drug-
drug pharmacokinetic interactions, which may become
especially relevant for those antimicrobials that may inhibit
(erythromycin or clarithromycin) cytochrome P450-mediated
drug metabolism [28].
Conversely, it is less evident that higher than standard
dosages of renally excreted drugs may be needed for optimal
exposure in patients with glomerular hyperfiltration [6,29]. Of
note, glomerular hyperfiltration may the consequence of
inotropic agents when hypotension does not revert with fluid
therapy. This increases cardiac indices [17], which in turn
lead to increased renal preload and so increased renal drug
clearance. Interestingly, a very recent prospective study
showed that glomerular hyperfiltration (defined as CLCr
>120 ml/minute per 1.73 m2) was a relatively frequent
occurrence among 89 critically ill patients [30]. The
percentage of patients exhibiting glomerular hyperfiltration
was 17.9% on the first morning of ICU admission, and
increased to as high as 30% during the first week of
admission. We are particularly concerned about the potential
role that glomerular hyperfiltration may play in increasing
mortality rate from bacterial infections in critically ill patients
treated with standard dosages of renally excreted anti-
microbials [31]. Therefore, we recommend that ICU physicians
conduct a daily reassessment of antimicrobial regimens in
accordance with daily measurement of CLCr, keeping in mind
that assessment of renal function not only must identify patients
with renal impairment but also must identify those with
glomerular hyperfiltration, in whom higher dosages of renally
excreted antimicrobials may be indicated [31].
Hypoalbuminaemia is another relevant cause of underdosing
in critically ill patients whenever highly protein bound anti-
microbials (teicoplanin, ertapenem or ceftriaxone) are used.
Hypoalbuminaemia is a frequently occurring condition in
patients with severe sepsis as a consequence of increased
albumin capillary escape rate through leaky endothelium or of
fluid overload. By increasing the unbound fraction, hypo-
albuminaemia may promote not only more extensive
distribution but also greater renal clearance [6]. It has been
shown that in severe hypoalbuminaemic critically ill patients
the free fraction of teicoplanin may be more than doubled
[32], with significantly higher elimination rate [33].
In this context there may be an increased risk for underdosing
due to improved elimination of drugs [6,30]. Therefore,
selecting higher dosages and/or alternative dosing regimens
focused at maximizing the pharmacodynamics of anti-
microbials might be worthwhile, with the intent being to
increase clinical cure rates among critically ill patients. Indeed,
different approaches should be pursued according to the type
of antibacterial activity exhibited by the various antimicrobials.
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Interestingly, ‘hit hard, hit fast’ - the statement originally
adopted by Paul Ehrlich in 1913 to emphasize the impor-
tance of taking strong, early action against parasitic infections
[34] - remains the strategy of choice with concentration-
dependent agents, such as fluoroquinolones and amino-
glycosides. The efficacy of these agents is related to the
achievement of high Cmax/MIC ratio (>10) and AUC/MIC ratio
(>100 to 125) [35]. Accordingly, high dosage, short-course
therapy regimens with a once daily administration schedule
(Figure 3) may yield more rapid bacterial killing or prevention
of resistance development [36-38].
An intriguing example comes from a recent clinical study that
compared the efficacies of two schedule regimens of
levofloxacin (750 mg every 24 hours for 5 days [n = 76] and
500 mg every 24 hours for 10 days [n = 83]) in the treatment
of hospitalized patients with community-acquired pneumonia
[37]. Clinical success rates among the two patient groups
did not differ significantly, regardless of the severity of
pneumonia (Pneumonia Severity Index class III or IV). Interest-
ingly, however, the percentage of patients with resolution of
some relevant symptoms (purulent sputum and fever) by day 3
of therapy was significantly higher among those who received
750 mg every 24 hours (purulent sputum: 48.4% versus
27.5% [P = 0.007]; fever: 48.4% versus 34.0% [P = 0.046]).
Accordingly, it may be speculated that high-dosage, short-
course regimens with concentration-dependent antimicro-
bials may be especially useful in terms of shortening the time
to resolution of symptoms in seriously ill patients.
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Table 1
Recommended dosing regimens of the most frequently used renally excreted antimicrobials according to renal function
Renal function
Antibiotic Increaseda Normal Moderately impaired Severely impaired
Piperacillin/tazobatam 16/2 g q24h CI [56,57]  4/0.5 g q6h 3/0.375 g q6h 2/0.25 g q6h
or 3.375 q6h EI over 
4 hours [51]
Cefotaxime 4 to 6 g q24h CI [14] or  2 g q6-8h 2 g q6-8h 1 g q6-8h
2 g q4-6h
Ceftazidime 4 to 6 g q24h CI [55,70] 2 g q8h 1 g q8-12h 0.5 to 1 g q24h
Cefepime 4 to 6 g q24h CI [71] or  2 g q8h 2 g q12h 1 g q24h
2 g q8h EI over 
3 hours [72]
Imipenem 500 mg q4h [46] or  500 mg q6h 250 mg q6h 250 mg q12h
250 mg q3h over 
3 hours CI [73]
Meropenem 1 g q6h over 6 hours  500 mg q6h 250 mg q6h 250 mg q12h
CI [54] 
Ertapenem ND 1 g q24h 1 g q24h 500 mg q24h
Gentamycin 9 to 10 mg/kg q24hb [74] 7 mg/kg q24hb [74,75] 7 mg/kg q36-48hb 7 mg/kg q48-96hb
Tobramycin 9 to 10 mg/kg q24hb [74] 7 mg/kg q24hb [74,75] 7 mg/kg q36-48hb 7 mg/kg q48-96hb
Amikacin 20 mg/kg q24hb [8,76] 15 mg/kg q24hb 15 mg/kg q36-48hb 15 mg/kg q48-96hb
Ciprofloxacin 600 mg q12h or  400 mg q12h 400 mg q12h 400 mg q24h
400 mg q8h [77-79]
Levofloxacin 500 mg q12h [80] 750 mg q24h [37] 500 mg q24h 500 mg q48h
Vancomycin 30 mg/kg q24h CIb 500 mg q6hb 500 mg q12hb 500 mg q24-72hb
[58,61]
Teicoplanin LD 12 mg/kg q12h for  LD 12 mg/kg q12h for  LD 12 mg/kg q12h for  LD 12 mg/kg q12h for 
3 to 4 doses; MD 6 mg/kg  3 to 4 doses; MD 4 to  3 to 4 doses; MD 2 to  3 to 4 doses; MD 2 to 
q12h [81,82]b 6 mg/kg q12h [81,83]b 4 mg/kg q12h [81,83]b 4 mg/kg q24h [81,83]b
Daptomycin ND 6 mg/kg q24h 6 mg/kg q24h 6 mg/kg q48h
Data derived from Clinical Pharmacology, Gold Standard Multimedia [84] unless otherwise specified. aSuggested on the basis of some clinical
and/or population pharmacokinetic studies. bGuided by therapeutic drug monitoring. CI, continuous infusion; EI, extended infusion; LD, loading
dose; MD, maintenance dose; ND, not defined; qxh, every x hours.Likewise, for aminoglycosides once-daily administration is
considered at least as efficacious as dosing three times a day
[39]. This is unsurprising, considering that in some clinical
studies Cmax/MIC ratio was found to be the pharmaco-
dynamic parameter most important to outcome [40]. Interest-
ingly, in a prospective study conducted in 89 critically ill
patients receiving a once-daily regimen of 7 mg/kg genta-
mycin or tobramycin [41], satisfactory Cmax/MIC ratios above
10 were observed in the majority of cases. However, in
patients with glomerular hyperfiltration and with extensive
burns over more than 15% of their body surface area, higher
than standard daily dosages of aminoglycosides may be
needed to reach adequate Cmax [42]. Additionally, once-daily
dosing may potentially be less nephrotoxic. Among 54
patients randomly assigned to receive tobramycin once daily
(n = 25) or in multiple daily doses (n = 29) for the treatment
of suspected or documented Gram-negative infection, a
significantly lower increase in urinary enzymes suggestive of
nephrotoxicity (N-acetyl-β-D-glucosaminidase and alanine
aminopeptidase) was documented in the once-daily group,
despite the administration of higher dosages [43].
Time-dependent antibiotics
In contrast to concentration-dependent agents, ‘achieve the
target quickly and maintain it’ is the optimal strategy with
time-dependent antibacterial agents, namely β-lactams,
glycopeptides and oxazolidinones, whose efficacy in severely
ill patients is related mainly to the maintenance of supra-
inhibitory concentrations. Indeed, the need for MIC coverage
for 100% of the dosing interval with time-dependent
antimicrobials is a matter of debate. Valid bacterial killing with
β-lactams may occur with a t>MIC of just a fraction of the
dosing interval (20% to 40% for carbapenems, 50% to 60%
for penicillins, and 60% to 70% for cephalosporins) [11].
However, it should not be overlooked that bacterial regrowth
may start when the concentration falls below the MIC [44],
and that a higher probability of in vivo microbiological success
has been demonstrated with a t>MIC of 90% to 100% of the
dosing interval [45]. Accordingly, it may reasonably be
suggested that early attainment and maintenance of plasma
trough concentration (Cmin) above the MIC should represent
the goal of therapy in daily clinical practice for critically ill
patients [5,46]. Indeed, the large inter-individual and intra-
individual pharmacokinetic variability observed in these
patients may result in unpredictable plasma concentrations
[45,47], such that TDM of plasma concentrations - whenever
feasible - should be considered an invaluable tool for tailoring
drug therapy in this context [8,48]. Furthermore, three step-
up approaches may be considered with the aim of maximizing
the efficacy of time-dependent antimicrobials under the same
total daily dose in critically ill patients.
The first step is to consider multiple daily dosing. A Monte
Carlo simulation study assessed the theoretical cumulative
fractions of response with carbapenems, among others [49].
It showed that 500 mg every 6 hours may be equivalent to
1 g every 8 hours both for imipenem and meropenem in terms
of achieving bactericidal pharmacodynamic targets for the
most relevant Gram-negative bacilli isolated from the ICU
(Pseudomonas aeruginosa,  Acinetobacter baumannii,
Escherichia coli and Klebsiella spp.). These data confirm the
previous findings of a retrospective analysis of a population-
based predictive model [50], which assessed the pharmaco-
dynamics of meropenem in febrile neutropenic patients with
bacteraemia. Accordingly, it may be speculated that, because
it carries less risk for subtherapeutic drug concentrations, the
strategy of increasing the frequency of dosing but with
smaller doses (500 mg every 6 hours) may help to reduce the
burden of carbapenem usage. In turn, this might contain the
spread of bacterial resistance due to antibiotic selective
pressure.
Although multiple administration of time-dependent antimicro-
bials at standard daily dosage might be useful in clinically
stable patients, this may not suffice in patients with
glomerular hyperfiltration and/or with infections with border-
line susceptible bacterial strains. An important option in such
cases may be to shorten the dosing interval. Interestingly, a
recent study analyzed imipenem plasma concentrations in
57 febrile neutropenic patients with a median CLCr of
105 ml/minute (range: 29 to 235 ml/minute) [46]. It was
predicted, by means of a population pharmacokinetic program,
that the recommended regimen of 500 mg every 6 hours might
ensure optimal pharmacodynamic exposure against the most
common pathogens, in terms of Cmin > MIC90, in only 53% of
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Figure 3
Pharmacodynamics of a concentration-dependent antimicrobial.
Shown is a comparison of the simulated drug concentration profile of a
concentration-dependent antimicrobial with an elimination half-life of
2 hours administered once daily or in two divided doses. Under the
same total daily dose, once daily administration ensures higher
Cmax/MIC ratio in presence of equal AUC/MIC ratio. Dotted line refers
to a MIC of 2 mg/l. AUC, area under the plasma concentration-time
curve; Cmax, peak plasma concentration; MIC, minimum inhibitory
concentration.patients. However, when considering higher imipenem
dosages (3 g/day) with the intent being to achieve a higher
percentage of simulated patients with adequate imipenem
Cmin in the presence of glomerular hyperfiltration, it was
demonstrated that the strategy of shortening the time to re-
dosing (500 mg every 4 hours) was much more effective than
that of increasing single dosage amount (1 g every 8 hours).
Another, less expensive strategy in these cases may be the
use of extended infusion, over 3 to 4 hours, of standard
multiple daily dosing (Figure 4). By ensuring more sustained
concentrations, this may increase the probability of success-
ful clinical outcome [50,51]. The effectiveness of this
approach was recently demonstrated for piperacillin-tazo-
bactam in an interesting retrospective comparative study [51]
that assessed the efficacy of two different schedule regimens
(3.375 over 240 minutes every 8 hours [n = 102] versus
3.375 over 30 minutes every 6 to 8 hours [n = 92]) for the
treatment of P. aeruginosa infections. Among patients who
were not critically ill (Acute Physiology and Chronic Health
Evaluation [APACHE] II score <17) the 14-day mortality rate
was not influenced by the administration schedule (6.6% for
extended infusion versus 3.7% for intermittent infusion;
P = 0.5), but among critically ill patients (APACHE II score
≥17) it was significantly lower for those patients who
received extended infusion therapy than for patients who
received intermittent infusion therapy (12.2% versus 31.6%;
P = 0.04). These findings strongly suggest that extended
infusion of β-lactams may improve clinical outcome in
critically ill patients with severe infections, and indicate that
continuous infusion may be the best approach in terms of
maximizing efficacy with time-dependent antimicrobials.
Indeed, the stability of an antibiotic in solution at room
temperature is an important consideration when choosing to
administer time-dependent antibiotics by continuous infusion
(Table 2). As a general rule, drugs that are stable at room
temperature for only a few hours must be prepared fresh and
changed regularly. This may be particularly relevant to the
anti-pseudomonal carbapenems meropenem and imipenem
[52]. In contrast, piperacillin/tazobactam, cefepime, ceftazi-
dime and vancomycin are stable at room temperature for at
least 24 hours [52,53].
The comparative efficacy of β-lactams administered by
continuous versus intermittent infusion was recently assessed
in three retrospective studies with the same design con-
ducted by Lorente and coworkers. In the first study [54] the
efficacy of 4 g/day meropenem by continuous infusion (1 g
over 360 minutes every 6 hours) versus intermittent infusion
(1 g over 30 minutes every 6 hours) was assessed in patients
with ventilator-associated pneumonia (VAP) due to Gram-
negative bacilli [54]. Despite there being no significant
differences between patient groups with regard to sex, age,
APACHE II score at ICU admission, diagnosis, and respon-
sible micro-organisms and their susceptibility to meropenem,
the group receiving medication by continuous infusion
(n = 42) exhibited a greater clinical cure rate than did the
group treated with intermittent infusion (n = 47) (90.47%
versus 59.57%; P < 0.001). Of note, when clinical cure rates
were considered in relation to meropenem susceptibility of
bacterial isolates, the percentage difference between groups
in positive outcome (in favour of continuous infusion) was
more relevant in the presence of less susceptible micro-
organisms (MIC ≥ 0.50: 80.95% versus 29.41% [P = 0.003];
MIC 0.25 to 0.49: 100% versus 76.67% [P = 0.03]).
In the second retrospective study [55] the efficacy of 4 g/day
ceftazidime by continuous infusion (2 g over 720 minutes
every 12 hours) versus intermittent infusion (2 g over 30 minutes
every 12 hours) was assessed using the same study design
in patients with VAP due to Gram-negative bacilli. Despite
there being no significant differences between patient groups
in baseline characteristics, the group receiving ceftazidime by
continuous infusion (n = 56) exhibited a greater clinical cure
rate than did the group treated with intermittent infusion
(n = 65) (89.3% versus 52.3%; P < 0.001). The percentage
difference in positive clinical outcome (in favour of continuous
infusion) was greater among patients with infection due to
less susceptible micro-organisms (MIC = 8 mg/l: 75.%
versus 14.3% [P = 0.03]; MIC = 4 mg/l: 90.0% versus
38.5% [P = 0.02]; MIC ≤2 mg/l: 92.1% versus 62.2%
[P < 0.001]).
In the third retrospective study [56] the efficacy of 16/2 g/day
piperacillin/tazobactam by continuous infusion (4/0.5 g over
360 minutes every 6 hours) versus intermittent infusion
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Figure 4
Pharmacodynamics of a time-dependent antimicrobial. Shown is a
comparison of the simulated drug concentration profile of a time-
dependent anitmicrobial with an elimination half-life of 1 hour
administered over 30 minutes or over 3 hours. The extended infusion
time increases the time for which the antibiotic concentration exceeds
the minimum inhibitory concentration (t>MIC). Dotted line refers to a
MIC of 8 mg/l.(4/0.5 g over 30 minutes every 6 hours) was assessed using
the same study design in patients with VAP due to Gram-
negative bacilli. Once again, despite there being no relevant
differences between patient groups with regard to baseline
characteristics, the group receiving pipercillin/tazobactam by
continuous infusion (n = 37) exhibited a greater clinical cure
rate than did the group treated with intermittent infusion
(n = 46) (89.2% versus 56.5%; P < 0.001). In this last study,
the percentage difference in positive clinical outcome (in
favour of continuous infusion) became significantly larger only
when patients presented with infection due to less
susceptible micro-organisms (MIC = 4 mg/l: 90.0% versus
76.0% [P = 0.20]; MIC = 8 mg/l: 88.9% versus 40%
[P = 0.02]; MIC = 16 mg/l: 87.5% versus 16.7% [P = 0.02]). 
A recent prospective pharmacokinetic/pharmacodynamic study
conducted in patients with VAP confirmed that continuous
infusion may be helpful in providing adequate alveolar
exposure with piperacillin/tazobactam, in terms of steady-
state ELF concentrations exceeding the susceptibility break-
point of 16 mg/l [57]. This was the case even when the
standard 16/2 g/day dosage was administered to patients
with normal renal function. Likewise, continuous infusion was
recently advocated as a potentially useful tool for improving
the efficacy of the standard vancomycin daily dose (30 mg/kg)
in the treatment of methicillin-resistant Staphylococcus
aureus infections due to micro-organisms with borderline
susceptibility [58], thus avoiding the need for larger daily
doses, which have been shown to increase the risk for
nephrotoxicity [59]. In a retrospective study conducted in
patients treated with vancomycin because of oxacillin-
resistant VAP, Rello and coworkers [13] demonstrated that
vancomycin by continuous infusion was independently
associated with lower mortality rates compared with
intermittent infusion (25% versus 54.2%; P = 0.02).
Continuous infusion may be the best way to maximize the
time-dependent activity of vancomycin because, under the
same daily dosage, it may achieve higher and more sustained
concentrations at the infection site but without increasing the
daily exposure in terms of AUC (Figure 5) [5,60-62]. That is
why we recently developed a prospectively validated dosing
nomogram to maximize the pharmacodynamics of vancomycin
administered by continuous infusion [58]; the aim of the
nomogram is to achieve plasma steady-state concentrations
of 15 to 20 mg/l rapidly in critically ill patients. Interestingly,
among 182 physicians who responded to a survey on
antibiotic usage habits in Italian ICUs (proposed at a
conference on anaesthesia and intensive care [SMART] held
in May 2007 in Milan, Italy), 78% indicated that they usually
administered vancomycin by continuous infusion (Pea F, Viale
P, unpublished data).
In a recent meta-analysis of nine randomized controlled trials
comparing continuous intravenous infusion with intermittent
intravenous administration of the same antibiotic regimen
[63], clinical failure was lower in patients receiving con-
tinuous infusion, albeit without statistical significance (pooled
odds ratio = 0.73, 95% confidence interval = 0.53 to 1.01).
However, in a subset of randomized controlled trials that
used the same total daily antibiotic dose for both intervention
arms, this difference was statistically significant (pooled odds
ratio = 0.70, 95% confidence interval = 0.50 to 0.98; fixed
and random effects models).
Although randomized clinical trials are clearly required to
confirm these findings, and prospective trials are needed to
address a management strategy based on TDM, it could
reasonably be suggested that continuous infusion is a
promising tool for improving clinical cure with time-dependent
antimicrobials, especially among the critically ill. This may be
more relevant in infections with borderline susceptible patho-
gens and/or in patients with glomerular hyperfiltration. Of
note, it must be recalled that when choosing continuous
infusion, an initial LD must always be administered,
irrespective of the patient’s renal function, in order to achieve
therapeutically effective concentrations rapidly and to limit
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Page 8 of 13
(page number not for citation purposes)
Table 2
Stability of time-dependent antibiotics in solution for intravenous infusion
Time of stability  Maximum 
at room  concentration 
temperature tested 
Antibiotic (+25°C; hours) (mg/l) Solvent
Piperacillin/tazobatam [52] >72 128,000 Sterile water for injection
Ceftazidime [52] 24 120,000 Sterile water for injection
Cefepime [52] 13 50,000 Sterile water for injection
Imipenem [52] 3.30 8,000 Sterile water for injection
Meropenem [52] 5.15 64,000 Sterile water for injection
Vancomycin [53] >696 NA Sterile water for injection, sodium chloride solution (0.9%; pH 5.4), 
dextrose solution (5%; pH 4.2)
Stability was defined as times during which antibiotic remains >90% stable in solution. NA, not applicable.risk for underexposure during the first few hours of treatment,
with continuous infusion starting immediately afterward. For a
comprehensive review of the potential role of continuous
infusion of time-dependent antimicrobials in the treatment of
infections in critically ill patients, readers are referred to
recent work reported by Roberts and coworkers [62].
Antimicrobial therapy in patients undergoing
continuous renal replacement therapy
It is worth noting that appropriate dosing of antimicrobial
agents in critically ill patients may be further complicated by
the application of continuous renal replacement therapy
(CRRT), especially when residual renal function coexists [64].
As a general rule (Table 3), drugs for which the kidney is the
predominant site of clearance and that may be extracted by
CRRT may need significant dosage increase as compared
with the setting of renal failure or even with intermittent
haemodialysis. This is usually the case for β-lactams, glyco-
peptides, aminoglycosides, levofloxacin and ciprofloxacin.
Conversely, drugs that are not normally cleared via the renal
route and that exhibit very low extraction during CRRT may
need unmodified dosages in comparison with normal renal
function, as in the case of linezolid and moxifloxacin. Clearly,
TDM is invaluable in such cases.
Conclusions
Appropriate antibiotic therapy in patients with severe sepsis
and septic shock should mean prompt achievement and
maintenance of optimal exposure at the infection site with
broad-spectrum antimicrobial agents administered in a timely
manner. Once the causative pathogens have been identified
and tested for in vitro susceptibility, subsequent de-
escalation of antimicrobial therapy should be applied
whenever feasible. Appropriateness of treatment is rarely
assessed in terms of adequate dosing schedule regimens.
Inadequate dosing schedules may lead to suboptimal expo-
sure at the infection site, increasing the risk for therapeutic
failure or selection of resistant bacteria. However, adminis-
tration of higher antibiotic doses than are required increases
the risk for adverse events. Therefore, TDM of plasma
concentrations should be encouraged whenever possible,
because these concentrations are difficult to predict in
critically ill patients, even when their renal function is
estimated using different formulae. Indeed, infections mainly
occur in tissue extracellular fluids, and it is the generally
accepted view that - once steady-state pharmacokinetics are
achieved - the unbound concentrations in plasma and extra-
cellular fluids are similar, even in the most severely ill patients
[65]. Therefore, assessment of antibiotic concentration in
plasma is a good surrogate for estimating antibiotic
concentration at the tissue infection site, provided that the
unbound concentration is measured. However, in certain
situations unbound concentrations at equilibrium may be
lower in tissues than in plasma. This is the case when active
efflux transport systems restrict tissue distribution [66], as
observed in brain [67], or in the presence of drug degra-
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Figure 5
Simulation of different administration schedules of 2 g daily vancomycin. Shown are simulated profiles of vancomycin daily plasma exposure
achievable in a young male with normal renal function when administering the fixed 30 mg/kg per day dose separated into two or four intermittent
infusions, or by continuous infusion (CI) after loading (loading dose [LD]). Simulation was performed using a two-compartment linear model by
means of the Abbottbase Pharmacokinetic Systems program (PKS; v 1.10) from Abbott Laboratories Diagnostics Division. The dotted/dashed line
refers to 10 mg/l. Reproduced with permission from Pea and coworkers [61]. CLCr, creatinine clearance; SCr, serum creatinine.Critical Care    Vol 13 No 3 Pea and Viale
Page 10 of 13
(page number not for citation purposes)
T
a
b
l
e
 
3
O
v
e
r
v
i
e
w
 
o
f
 
d
o
s
i
n
g
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
 
f
o
r
 
e
n
s
u
r
i
n
g
 
a
p
p
r
o
p
r
i
a
t
e
 
p
h
a
r
m
a
c
o
d
y
n
a
m
i
c
 
e
x
p
o
s
u
r
e
 
w
i
t
h
 
s
o
m
e
 
a
n
t
i
m
i
c
r
o
b
i
a
l
 
a
g
e
n
t
s
 
d
u
r
i
n
g
 
C
R
R
T
P
r
o
p
o
s
e
d
 
o
p
t
i
m
a
l
 
P
D
 
t
a
r
g
e
t
 
v
e
r
s
u
s
 
U
s
u
a
l
 
d
o
s
a
g
e
 
H
i
g
h
e
s
t
 
d
o
s
a
g
e
 
A
n
t
i
b
i
o
t
i
c
s
u
s
c
e
p
t
i
b
l
e
 
p
a
t
h
o
g
e
n
s
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
C
r
i
t
i
c
a
l
 
f
a
c
t
o
r
s
 
r
e
s
p
o
n
s
i
b
l
e
 
f
o
r
 
h
i
g
h
e
r
 
d
o
s
a
g
e
s
M
e
r
o
p
e
n
e
m
C
m
i
n
>
 
4
 
m
g
/
l
0
.
5
 
g
 
q
8
h
 
t
o
 
0
.
5
 
q
6
h
1
 
g
 
q
4
-
6
h
V
e
r
y
 
h
i
g
h
 
Q
U
F
>
2
 
t
o
 
3
 
l
/
h
o
u
r
 
a
n
d
/
o
r
 
Q
D
>
1
 
t
o
 
2
 
l
/
h
o
u
r
S
i
g
n
i
f
i
c
a
n
t
 
r
e
s
i
d
u
a
l
 
r
e
n
a
l
 
f
u
n
c
t
i
o
n
 
(
C
L
C
r
>
5
0
 
m
l
/
m
i
n
u
t
e
)
B
o
r
d
e
r
l
i
n
e
 
s
u
s
c
e
p
t
i
b
l
e
 
i
s
o
l
a
t
e
s
 
(
M
I
C
s
 
o
f
 
8
 
t
o
 
1
6
 
m
g
/
l
)
I
m
i
p
e
n
e
m
/
c
i
l
a
s
t
a
t
i
n
C
m
i
n
>
4
 
m
g
/
l
0
.
5
 
g
 
q
8
h
 
t
o
 
0
.
5
 
g
 
q
6
h
F
l
u
c
l
o
x
a
c
i
l
l
i
n
C
m
i
n
>
4
 
m
g
/
l
4
g
 
q
8
h
a
P
i
p
e
r
a
c
i
l
l
i
n
/
t
a
z
o
b
a
c
t
a
m
C
m
i
n
>
1
6
 
t
o
 
6
4
 
m
g
/
l
4
.
0
/
0
.
5
 
g
 
q
8
h
4
.
0
/
0
.
5
 
g
 
q
4
h
S
i
g
n
i
f
i
c
a
n
t
 
r
e
s
i
d
u
a
l
 
r
e
n
a
l
 
f
u
n
c
t
i
o
n
 
(
C
L
C
r
>
5
0
 
m
l
/
m
i
n
u
t
e
)
C
e
f
e
p
i
m
e
C
m
i
n
>
8
 
m
g
/
l
1
 
t
o
 
2
 
g
 
q
1
2
h
2
 
g
 
q
8
h
V
e
r
y
 
h
i
g
h
 
Q
U
F
>
2
 
t
o
 
3
 
l
/
h
o
u
r
 
a
n
d
/
o
r
 
Q
D
>
1
 
t
o
 
2
 
l
/
h
o
u
r
R
e
s
i
d
u
a
l
 
C
L
C
r
>
5
0
 
m
l
/
m
i
n
u
t
e
C
e
f
p
i
r
o
m
e
C
m
i
n
>
8
 
m
g
/
l
1
 
g
 
q
1
2
h
2
 
g
 
q
8
h
H
i
g
h
 
n
o
n
-
C
R
R
T
 
r
e
l
a
t
e
d
 
c
o
m
p
e
n
s
a
t
o
r
y
 
C
L
A
d
s
o
r
p
t
i
o
n
 
t
o
 
p
o
l
y
s
u
l
f
o
n
e
 
h
a
e
m
o
f
i
l
t
e
r
C
e
f
t
a
z
i
d
i
m
e
C
m
i
n
>
8
 
m
g
/
l
1
 
g
 
q
8
h
 
o
r
 
3
 
g
/
d
a
y
 
C
I
2
 
t
o
 
3
 
q
8
h
V
e
r
y
 
h
i
g
h
 
C
L
T
(
2
-
 
t
o
 
3
-
f
o
l
d
 
h
i
g
h
e
r
 
t
h
a
n
 
i
n
 
h
e
a
l
t
h
y
 
v
o
l
u
n
t
e
e
r
s
)
C
e
f
t
r
i
a
x
o
n
e
C
m
i
n
>
8
 
m
g
/
l
2
 
g
 
q
2
4
h
T
e
i
c
o
p
l
a
n
i
n
C
m
i
n
=
 
1
0
 
t
o
 
2
0
 
m
g
/
l
L
D
 
6
 
m
g
/
k
g
 
q
1
2
h
 
f
o
r
 
4
 
d
o
s
e
s
L
D
 
6
 
m
g
/
k
g
 
q
1
2
h
 
f
o
r
 
4
 
d
o
s
e
s
H
y
p
o
a
l
b
u
m
i
n
a
e
m
i
a
M
D
 
3
 
m
g
/
k
g
 
q
2
4
h
M
D
 
6
 
m
g
/
k
g
 
q
2
4
h
S
i
g
n
i
f
i
c
a
n
t
 
r
e
s
i
d
u
a
l
 
r
e
n
a
l
 
f
u
n
c
t
i
o
n
 
(
C
L
C
r
>
5
0
 
m
l
/
m
i
n
u
t
e
)
V
a
n
c
o
m
y
c
i
n
C
m
i
n
=
 
1
5
 
t
o
 
2
0
 
m
g
/
l
0
.
2
5
 
t
o
 
0
.
5
 
g
 
q
1
2
h
0
.
5
 
g
 
q
6
h
V
e
r
y
 
h
i
g
h
 
C
R
R
T
 
f
l
o
w
 
r
a
t
e
s
 
(
Q
U
F
±
 
Q
D
o
f
 
6
 
l
/
h
o
u
r
)
C
i
p
r
o
f
l
o
x
a
c
i
n
C
m
a
x
/
M
I
C
 
>
8
 
t
o
 
1
0
0
.
4
 
g
 
q
1
2
h
A
U
C
/
M
I
C
 
>
1
0
0
L
e
v
o
f
l
o
x
a
c
i
n
C
m
a
x
/
M
I
C
 
>
8
 
t
o
 
1
0
0
.
5
 
g
 
q
4
8
h
 
(
o
r
 
0
.
2
5
 
q
2
4
h
)
0
.
5
 
g
 
q
2
4
h
V
e
r
y
 
h
i
g
h
 
Q
U
F
>
3
 
l
/
h
o
u
r
A
U
C
/
M
I
C
 
>
1
0
0
M
o
x
i
f
l
o
x
a
c
i
n
C
m
a
x
/
M
I
C
 
>
8
 
t
o
 
1
0
0
.
4
 
g
 
q
2
4
h
a
A
U
C
/
M
I
C
 
>
1
0
0
O
f
l
o
x
a
c
i
n
C
m
a
x
/
M
I
C
 
>
8
 
t
o
 
1
0
0
.
4
 
g
 
q
8
h
a
A
U
C
/
M
I
C
 
>
1
0
0
L
i
n
e
z
o
l
i
d
C
m
i
n
>
4
 
m
g
/
l
0
.
6
 
g
 
q
1
2
h
0
.
6
 
g
 
q
8
h
V
e
r
y
 
h
i
g
h
 
C
L
C
R
R
T
H
i
g
h
 
n
o
n
-
C
R
R
T
-
r
e
l
a
t
e
d
 
C
L
 
i
n
 
s
o
m
e
 
c
r
i
t
i
c
a
l
l
y
 
i
l
l
 
p
a
t
i
e
n
t
s
a
D
o
s
a
g
e
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
 
f
r
o
m
 
a
 
s
i
n
g
l
e
 
s
t
u
d
y
.
 
A
U
C
,
 
a
r
e
a
 
u
n
d
e
r
 
t
h
e
 
p
l
a
s
m
a
 
c
o
n
c
e
n
t
r
a
t
i
o
n
-
t
i
m
e
 
c
u
r
v
e
;
 
C
I
,
 
c
o
n
t
i
n
u
o
u
s
 
i
n
f
u
s
i
o
n
;
 
C
L
C
r
,
 
c
r
e
a
t
i
n
i
n
e
 
c
l
e
a
r
a
n
c
e
;
 
C
L
C
R
R
T
,
 
e
x
t
r
a
c
o
r
p
o
r
e
a
l
 
c
l
e
a
r
a
n
c
e
;
 
C
L
T
,
t
o
t
a
l
 
b
o
d
y
 
c
l
e
a
r
a
n
c
e
;
 
C
m
a
x
,
 
p
e
a
k
 
p
l
a
s
m
a
 
c
o
n
c
e
n
t
r
a
t
i
o
n
;
 
C
m
i
n
,
 
t
r
o
u
g
h
 
p
l
a
s
m
a
 
c
o
n
c
e
n
t
r
a
t
i
o
n
;
 
C
R
R
T
,
 
c
o
n
t
i
n
u
o
u
s
 
r
e
n
a
l
 
r
e
p
l
a
c
e
m
e
n
t
 
t
h
e
r
a
p
y
;
 
C
V
V
H
D
F
,
 
c
o
n
t
i
n
u
o
u
s
 
v
e
n
o
v
e
n
o
u
s
 
h
a
e
m
o
d
i
a
f
i
l
t
r
a
t
i
o
n
;
L
D
,
 
l
o
a
d
i
n
g
 
d
o
s
e
;
 
M
D
,
 
m
a
i
n
t
e
n
a
n
c
e
 
d
o
s
e
;
 
M
I
C
,
 
m
i
n
i
m
u
m
 
i
n
h
i
b
i
t
o
r
y
 
c
o
n
c
e
n
t
r
a
t
i
o
n
;
 
P
D
,
 
p
h
a
r
m
a
c
o
d
y
n
a
m
i
c
;
 
q
x
h
,
 
e
v
e
r
y
 
x
 
h
o
u
r
s
;
 
Q
D
,
 
d
i
a
l
y
s
a
t
e
 
f
l
o
w
 
r
a
t
e
;
 
Q
U
F
,
 
u
l
t
r
a
f
i
l
t
r
a
t
i
o
n
 
f
l
o
w
 
r
a
t
e
.
 
A
d
a
p
t
e
d
 
w
i
t
h
p
e
r
m
i
s
s
i
o
n
 
f
r
o
m
 
P
e
a
 
a
n
d
 
c
o
w
o
r
k
e
r
s
 
[
6
4
]
.dation within tissues, such as in the peritoneal cavity of
patients with severe secondary peritonitis [14,68].
Unfortunately, clinical data in this area are still lacking, and
much work remains to be done in this field before useful
antibiotic regimen recommendations can be developed. Until
such recommendations become available, the goal of appro-
priate  antibiotic therapy must be pursued resolutely and
with continuity, in view of the ongoing explosion of anti-
biotic-resistant infections that plague the ICU setting and of
the continued decrease in new antibiotics emerging [69].
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